Patents Examined by Robert S. Landsman
  • Antibodies that bind to dengue virus serotype 4 (DENV4) and methods of making and using the same
    Patent number: 11407818
    Abstract: The present disclosure relates to polypeptides that specifically bind to Dengue virus non¬structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIH YS GGTN YNPS LKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: August 9, 2022
    Assignee: The United States of America, as Represented By The Secretary, Department of Health and Human Services
    Inventors: Elizabeth Anne Hunsperger, Tesfaye Gelanew Taye
  • Polypeptides which bind to interleukin-6 receptor (IL-6R)
    Patent number: 11401327
    Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain which binds to IL-6R, wherein the immunoglobulin chain variable domain comprises three complementarity determining regions (CDR1-CDR3) and four framework regions (FR1-FR4), wherein CDR1-CDR3 and FR1-FR4 are as defined in the specification.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: August 2, 2022
    Assignee: SORRISO PHARMACEUTICALS, INC.
    Inventors: Scott Crowe, Tim Carlton, Marion Cubitt, Kevin Roberts, Luana Maggiore, Mike West, Keith Ray
  • Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist
    Patent number: 11402391
    Abstract: Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: August 2, 2022
    Assignee: IncellDx, Inc.
    Inventors: Bruce K. Patterson, Edgar B. Francisco, Amruta Pise, Emily Long
  • Anti-colony stimulating factor 1 receptor (CSF1R) antibodies and methods of use thereof for treating cancer
    Patent number: 11396549
    Abstract: The present disclosure provides antibodies, including antibody fusions, which specifically bind to human CSF1 receptor protein (huCSF1R) and are capable of decreasing, inhibiting, and/or fully-blocking immune regulatory effects mediated by huCSF1R, such as regulation of TAMs in the tumor microenvironment. Additionally, the antibodies include fusions with the cytokine inhibitory factor, IL10, which can replenish and/or activate CD8+ T-cell cytotoxicity in the tumor microenvironment. The present disclosure also provides methods of using the antibodies (and compositions thereof) to treat diseases and conditions responsive to decreasing, inhibiting and/or blocking immune regulatory function or activity mediated by CSF1 binding to CSF1R.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: July 26, 2022
    Assignee: ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED
    Inventors: Hung-Kai Chen, Daw-Tsun Shih, Jing-Yi Huang, Huey-Wen Hsiao, Chih-Lun Hsiao
  • Methods of intravenouisly delivering anti-transferrin antibody/oligonucleotide complexes to subjects having muscular dystrophy
    Patent number: 11390682
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: July 19, 2022
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden
  • Recombinant vector and expression system comprising a nucleic acid encoding a variable lymphocyte receptor (VLR)
    Patent number: 11384134
    Abstract: This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: July 12, 2022
    Assignee: Emory University
    Inventors: Brantley R. Herrin, Max Dale Cooper, Rudolf Ehrhardt
  • Anti-leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) monoclonal antibodies and method of use thereof to treat cancer
    Patent number: 11377491
    Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: July 5, 2022
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: X. Charlene Liao, Qiang Liu, Zhiqiang An, Ningyan Zhang, Xun Gui, Chengcheng Zhang, Mi Deng, Jingjing Xie
  • Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
    Patent number: 11377503
    Abstract: The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Stéphanie Chanteux, Laurent Gauthier, Nicolas Gourdin, Carine Paturel, Ivan Perrot, Benjamin Rossi
  • Anti-human IgG4 monoclonal antibody and methods of making and using same
    Patent number: 11372001
    Abstract: Provided are: a monoclonal antibody against human IgG4, for which the epitope is present in the CH3 of human IgG4 given by SEQ ID NO: 4; a hybridoma that produces the monoclonal antibody; a method for detecting IgG4 using the monoclonal antibody; and a kit used in this method.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: June 28, 2022
    Assignee: NITTO BOSEKI CO., LTD.
    Inventors: Yuya Teruuchi, Yuri Matsuki, Kazumitsu Inagaki, Daisuke Sasaki, Haruka Kashiwagura
  • Methods for promoting t cells response by administering an antagonist of human c-type lectin-like receptor 1 (CLEC-1)
    Patent number: 11365257
    Abstract: The present invention relates to methods for promoting T cells response. The inventors examined the expression and function of CLEC-1 in human DCs and demonstrated for the first time a cell-surface expression. They investigated its functional role following triggering on orchestration of T-cell responses. The inventors showed in vitro and in vivo with CLEC-1 deficient rats and rat CLEC-1 Fc fusion protein that disruption of CLEC-1 signalling enhances in vitro Th17 activation and in vivo enhances T cell priming and Th17 and Th1 activation. In particular, the present invention relates to CLEC-1 antagonists for promoting T cells response in a subject in need thereof.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: June 21, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE NANTES, OSE IMMUNOTHERAPEUTICS
    Inventors: Elise Chiffoleau, Géraldine Teppaz, Nicolas Poirier, Bernard Vanhove, Vanessa Gauttier
  • Formulation of tocilizumab and method for treating COVID-19 by inhalation
    Patent number: 11365248
    Abstract: The present invention is directed to formulations containing the anti-IL-6 therapeutic monoclonal antibody tocilizumab and pharmaceutically acceptable excipients that can be administered using a soft mist inhaler or a nebulizer.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: June 21, 2022
    Assignee: ANOVENT PHARMACEUTICAL (U.S.), LLC
    Inventors: Cai Gu Huang, Hitesh Bhagavanbhai Mangukiya
  • Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels
    Patent number: 11359017
    Abstract: The present invention provides a novel method of obtaining data for predicting the onset of an adverse event due to administration of at least one antibody drug selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA4 antibody, and an antigen-binding fragment thereof, or a novel method of predicting the onset of the adverse event. More specifically, the present invention provides a method of obtaining data for predicting the onset of an adverse event or a method of predicting the onset of the adverse event, comprising measuring a level of at least one marker selected from sCD163 and CXCL5 in a biological sample collected from a subject administered the antibody drug.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 14, 2022
    Assignee: TOHOKU UNIVERSITY
    Inventor: Taku Fujimura
  • Method for reducing an immune response by administering an immune evading adeno-associated AAV8 or AAVDJ viral vector
    Patent number: 11332727
    Abstract: Described herein are methods of avoiding an immune response in a subject being administered a regimen requiring Cas9 in order to optimize and broaden the application of CRIPSR based therapeutics comprising administering immune orthogonal Cas9. Also described herein are methods to modify a Cas9 protein by swapping highly immunogenic peptides or amino acids with less immunogenic counterparts. These methods are particularly useful to enable the application of Cas9 arsenal for repeat treatments. Further provided are Cas9 proteins modified to reduce immunogenicity.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: May 17, 2022
    Assignee: The Regents of the University of California
    Inventors: Prashant Mali, Ana Moreno Collado, Nathan Palmer
  • Antibody capable of binding to norovirus, composite, detection device and method using the same
    Patent number: 11312759
    Abstract: The present invention provides an antibody including a structural domain represented by the following amino acid sequence, in an N- to C-direction, N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein the antibody further includes a protein molecule bound to the structural domain; the structural domain is capable of binding to a norovirus; FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; any one of the following requirements (i)-(iii) is satisfied.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: April 26, 2022
    Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.
    Inventor: Keiko Yugawa
  • Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same
    Patent number: 11312771
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 26, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng
  • Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer
    Patent number: 11306154
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: April 19, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Maria Amann, Peter Bruenker, Christina Claus, Claudia Ferrara Koller, Sandra Grau-Richards, Christian Klein, Viktor Levitski, Ekkehard Moessner, Joerg Thomas Regula, Pablo Umana
  • Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist
    Patent number: 11306150
    Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: April 19, 2022
    Assignees: Bristol-Myers Squibb Company, Five Prime Therapeutics, Inc.
    Inventors: Robert J. Johnston, Andrew Rankin, Arathi Krishnakumar, Paul O. Sheppard, Arvind Rajpal
  • Artificial chemical entity comprising a DNA oligonucleotide aptamer that selectively binds MUC1 antigen
    Patent number: 11299740
    Abstract: Disclosed are artificial chemical entities, pharmaceutical compositions comprising such chemical entities and methods using the chemical entities. In some embodiments, the artificial chemical entity comprises a biomarker-bonding portion that selectively binds to a specified biomarker and an immune-response trigger that under in vivo conditions leads to positioning of an antibody Fc region in proximity of the biomarker to which the biomarker-bonding portion is bound.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: April 12, 2022
    Inventors: Ofer Nussbaum, Boaz Musafia
  • Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist
    Patent number: 11292840
    Abstract: The invention provides methods of treating cancer and methods for selecting treatment approaches for cancer.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: April 5, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Christopher Harvey, Deborah Law, Amanda Elizabeth Hanson, Martin Yu Fan
  • Complex comprising anti-transferrin receptor antibody covalently linked to an oligonucleotide that targets DUX4 RNA
    Patent number: 11286305
    Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: March 29, 2022
    Assignee: Dyne Therapeutics, Inc.
    Inventors: Romesh R. Subramanian, Mohammed T. Qatanani, Timothy Weeden